LAS VEGAS — In this Healio Video Perspective, Dante J. Pieramici, MD, discusses a trial investigating contrast sensitivity as a visual functional test in patients with nonproliferative diabetic retinopathy and retinal nonperfusion.
At Clinical Trials at the Summit, Pieramici said that the MAGIC trial will randomly assign patients to receive either monthly Vabysmo (faricimab, Genentech) for 1 year followed by quarterly treatments or observation for 1 year followed by faricimab in the second year.
“The primary endpoint of this trial is going to be the change in area of retinal